NeuroOne Medical Technologies Corporation
Moat Score — NeuroOne Medical Technologies Corporation
Total Moat Score
8 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | NeuroOne's thin-film electrode design is patent-protected and has already converted into four FDA 510(k) clearances (Evo Cortical, Evo sEEG, OneRF Brain, OneRF TN), a real regulatory and technical moat for a company of its size. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a small-scale device maker reliant on a distribution partner for most of its commercial volume, NeuroOne has no manufacturing or purchasing cost advantage versus much larger competitors like Medtronic or Boston Scientific. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | Pricing for NeuroOne's cleared products is constrained by hospital purchasing processes and comparison to larger incumbents' established electrode and ablation products, leaving limited room to price at a premium. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in NeuroOne's business; each hospital or surgical adoption is an independent sale rather than one that compounds in value with other customers. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once surgical teams are trained on NeuroOne's electrode handling and ablation workflow, there is real procedural switching friction, but it is far short of the deep system-level lock-in seen with capital equipment platforms from larger device companies. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | NeuroOne remains a small, early-commercial company that must fund growth through periodic capital raises, and in its pipeline markets (spinal cord stimulation, basivertebral ablation) it faces vastly larger-scale incumbents rather than benefiting from any efficient-scale barrier of its own. |